Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Zevra Therapeutics (ZVRA) over the last 6 years, with Q3 2025 value amounting to -$6.6 million.

  • Zevra Therapeutics' Other Non Operating Income rose 258.28% to -$6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 165027.41%. This contributed to the annual value of $6.2 million for FY2024, which is 34028.37% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Other Non Operating Income of -$6.6 million as of Q3 2025, which was up 258.28% from $135.4 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Other Non Operating Income registered a high of $135.4 million during Q2 2025, and its lowest value of -$16.9 million during Q1 2021.
  • For the 3-year period, Zevra Therapeutics' Other Non Operating Income averaged around $12.0 million, with its median value being -$3.4 million (2025).
  • Within the past 5 years, the most significant YoY rise in Zevra Therapeutics' Other Non Operating Income was 747007.83% (2025), while the steepest drop was 258.28% (2025).
  • Quarter analysis of 3 years shows Zevra Therapeutics' Other Non Operating Income stood at $789000.0 in 2021, then surged by 854.5% to $7.5 million in 2024, then plummeted by 187.15% to -$6.6 million in 2025.
  • Its last three reported values are -$6.6 million in Q3 2025, $135.4 million for Q2 2025, and -$3.4 million during Q1 2025.